Clinical trials
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) clinical trials
Below are recruiting allogeneic hematopoietic stem cell transplantation (hsct) clinical trials, each written for real people, not researchers. We’re tracking 120 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07791849Recruiting
Comparing two stomach protectors after stem cell transplant
This study compares two medications, GMPA and PPI, that protect the stomach during a stem cell transplant. It aims to see which one is better at preventing stomach problems and reducing the risk of a complication called graft-versus-host disease (aGVHD), where donor cells attack the patient's body.
HangzhouAges 12–70 - NCT07791576RecruitingPhase 2
Custom dosing of anti-thymocyte globulin for stem cell transplant
This trial tests whether giving anti-thymocyte globulin (ATG) based on a person's own body chemistry can reduce side effects and improve outcomes in stem cell transplants. It is for people with certain blood cancers who are in their first or second remission.
Beijing, Beijing MunicipalityAges 14–65 - NCT07347990Recruiting
Iptacopan for high-risk TA-TMA after stem cell transplant
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
Hangzhou, ChinaAges 12 years+ - NCT07771855RecruitingPhase 2
Antibody treatment for chronic lung disease after stem cell transplant
This study tests a new antibody medicine called tezelumab for patients who develop a breathing problem called bronchiolitis obliterans syndrome (BOS) after a stem cell transplant. The trial aims to see if this medicine can reduce flare-ups and improve lung function.
BesançonAges 18 years+ - NCT05632380RecruitingPhase 1/Phase 2
Stem cell transplant with CAR-T therapy for high-risk myeloma
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07490288Recruiting
Venetoclax, azacitidine, and mitoxantrone for new AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
Tianjin, Tianjin MunicipalityAges 14–100 - NCT06861257Recruiting
Treosulfan monitoring in pediatric stem cell transplant
This study watches how the chemotherapy drug Treosulfan works in children getting a stem cell transplant. The goal is to make sure the dose is just right for each child.
Bologna, bOLOGNAAges Up to 18 years - NCT06769191RecruitingEarly Phase 1
CD7 car-t, stem cell transplant, and kidney transplant for SIOD
This trial tests a sequence of treatments for SIOD (a genetic condition causing immune and kidney problems). First, you receive CD7 car-t cells, then a stem cell transplant from a family donor, followed by a kidney transplant from the same donor. The goal is to see if this approach is safe and can help your body accept the new kidney.
Hangzhou, ZhejiangAges Any age - NCT06328127Recruiting
Positive psychology program for stem cell transplant survivors
This study tests a positive psychology program—simple exercises to help you feel better emotionally—for people who are about 3 months past a donor stem cell transplant. It's done over the phone, so you can join from home.
Tampa, FloridaAges 18 years+ - NCT06076226Recruiting
Donor telomere length and leukemia transplant outcomes
This trial looks at whether the length of telomeres (the protective caps at the ends of chromosomes) in donor blood cells affects recovery for people with acute leukemia who receive a stem cell transplant. It aims to see if a simple donor blood test can predict how well the transplant works.
Hangzhou, ZhejiangAges 5–90 - NCT05605574Recruiting
Advance care planning talks for young transplant patients
This study tests a structured set of conversations about future medical care (advance care planning) for adolescents and young adults who are preparing for a stem cell transplant. It also involves a caregiver (and the care team) to help ensure the discussions are understood, documented, and completed at the right times.
Baltimore, MarylandAges 18–120 - NCT05745532RecruitingEarly Phase 1
Autologous stem cell treatment to improve beta thalassemia major
This early-phase trial tests a new way to restore working blood-making cells using your own stem cells for people with transfusion-dependent beta thalassemia major. The goal is to improve safety and blood results, and possibly reduce problems from the disease.
Shenzhen, GuangdongAges 8–16 - NCT07693881Recruiting
Preventing EBV reactivation with rituximab after stem cell transplant in children
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
GuangzhouAges Up to 18 years - NCT07214688RecruitingPhase 2
Transplant Prep with Chemo, Radiation, and GVHD Prevention for Blood Cancers
This trial tests a standard transplant preparation (chemotherapy and low-dose radiation) followed by a special drug (PTCy) to prevent graft-versus-host disease after a donor stem cell transplant for blood cancers. It may help improve transplant success and reduce complications.
Washington D.C., District of ColumbiaAges 18–65 - NCT07047183RecruitingPhase 2
A study of venetoclax and azacitidine before stem cell transplant for MDS
This trial tests a combination of two drugs (venetoclax and azacitidine) given before a stem cell transplant to see if it improves outcomes for people with a certain type of myelodysplastic syndromes (MDS) that is higher risk. If you have higher-risk MDS and are planning a stem cell transplant, this may be an option.
Changchun, JilinAges 18 years+ - NCT06093867Recruiting
Tracking lung health after stem cell transplant
This study follows people getting a stem cell transplant to watch for lung problems, like infections or other lung diseases, that can happen after the transplant. The goal is to catch these issues early.
Bethesda, MarylandAges 5–70 - NCT06083129RecruitingPhase 3
Preventing GVHD after stem cell transplant in older adults
This trial tests two different medicines (ATG-thymoglobulin and ATLG-grafalon) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for older adults with certain blood cancers who have a matched unrelated donor.
AmiensAges 50–70 - NCT07559695Recruiting
Menin inhibitor maintenance therapy after stem cell transplant
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Suzhou, JiangsuAges 15 years+ - NCT07101588RecruitingPhase 4
Ruxolitinib and decitabine before stem cell transplant for AML
This trial tests whether adding two drugs (ruxolitinib and decitabine) to the standard chemotherapy before a stem cell transplant can help prevent leukemia from coming back. It is for people with acute myeloid leukemia who have a suitable donor and are otherwise healthy enough for transplant.
Beijing, Beijing MunicipalityAges 14–75 - NCT06075563Recruiting
Total Lymphoid Irradiation for Children's Stem Cell Transplant
This trial tests a special type of radiation (total lymphoid irradiation) as part of the preparation for a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for children who need a transplant but don't have a fully matched sibling donor.
Hong KongAges Up to 18 years - NCT06702111Recruiting
Outcomes after donor stem cell transplant
This study looks at how well patients do after receiving a stem cell transplant from a donor (called an allogeneic transplant). It aims to better understand the long-term outcomes and help improve care for future patients.
Hong KongAges 18 years+ - NCT07341698Recruiting
Prehabilitation before stem cell transplant for blood cancer
This trial tests a prehabilitation program for patients with blood cancer who are scheduled for an allogeneic stem cell transplant. The goal is to help improve your physical and emotional strength before the transplant.
Copenhagen, DenmarkAges 18 years+ - NCT07029958RecruitingPhase 4
Transplant protocol for EBV-related T/NK lymphoproliferative disease
This trial tests a stronger transplant conditioning regimen to treat a rare immune disorder caused by the Epstein-Barr virus. It aims to improve outcomes and reduce a complication called graft-versus-host disease, where donor cells attack the patient's body.
BeijingAges birth–18 years - NCT06912347Enrolling by invitation
Herbal therapy to prevent infection after stem cell transplant
This trial tests whether a special herbal treatment applied to the skin can help prevent infections around the bottom that are caused by diarrhea after a stem cell transplant. It may be an option for people who are getting a transplant for the first time.
Shanghai, Shanghai MunicipalityAges 14–70
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for allogeneic hematopoietic stem cell transplantation (hsct)?
- Yes. Clin2 currently lists 120 recruiting allogeneic hematopoietic stem cell transplantation (hsct) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a allogeneic hematopoietic stem cell transplantation (hsct) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a allogeneic hematopoietic stem cell transplantation (hsct) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Hematopoietic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplant
- Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.